People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Second Sight Medical Products Inc | — | Biotechnology | Series B | $130.9M | $807.7M | 2009 |
| eyeBrain Medical, Inc. | — | Biotechnology | Series C | $126.3M | $1.2B | 2021 |
| ViaLase, Inc. | — | Other Health Care | Series C | $84.1M | $395.6M | 2019 |
| RxSight, Inc. | — | Other Health Care | Series C | $76.4M | $1.1B | 2017 |
| Neovista Inc | — | Other Health Care | Series B | $63.3M | $114.9M | 2009 |
| Allegro Ophthalmics, LLC | — | Pharmaceuticals | Series B | $60.4M | $115.9M | 2018 |
| TearClear Corp. | — | Pharmaceuticals | Series B | $52.4M | $122.5M | 2017 |
| Oculeve, Inc. | — | Other Health Care | Series B | $33.2M | $368.9M | 2012 |
| Lensx Lasers Inc | — | Biotechnology | Series B | $22.4M | $887.5M | 2009 |
| CorneaGen Inc. | — | Other Health Care | Series A | $17.0M | $40.4M | 2016 |
| OneFocus Vision, Inc. | — | Other Health Care | Seed | $2.2M | $54.6M | 2015 |
William Link at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Link on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| J. Andy Corley | 2 | 5 |
| Scott Cooper | 2 | 5 |
| Stephen Martin | 2 | 5 |
| Tom Frinzi | 2 | 3 |
| Shelley Thunen | 2 | 3 |
| William T. Link | 2 | 2 |
| Ali Behbahani | 1 | 17 |
| Richard Lindstrom | 1 | 13 |
| Brook Byers | 1 | 13 |
| Rick Lewis | 1 | 10 |
| William J. Link | 1 | 10 |
| Juliet Bakker | 1 | 9 |
| David Guyer | 1 | 8 |
| Tyler Stowater | 1 | 7 |
| Ryan Schwarz | 1 | 7 |
| Eric Bednarski | 1 | 7 |
| Bruce Robertson | 1 | 7 |
| William Greene | 1 | 6 |
| Robert Greenberg | 1 | 6 |
| Richard Harrison | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.